Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation...

Area of Science:

• Cardiovascular Medicine
• Hematology
• Medical Technology

Background:

• Antithrombotic agents are crucial for managing arterial and venous thrombosis in cardiovascular diseases.
• Current monitoring tools lack the ability to simultaneously assess diverse antithrombotic therapies like dual antiplatelet therapy and direct oral anticoagulants.
• Effective monitoring is essential for optimizing treatment and minimizing bleeding risks in patients with conditions such as coronary artery disease and atrial fibrillation.

Purpose of the Study:

• To evaluate the Total Thrombus-Formation Analysis System (T-TAS) as a tool for quantitatively analyzing whole blood thrombogenicity.
• To assess the utility of T-TAS in monitoring the antithrombotic effects of various agents, including antiplatelet therapies and anticoagulants.
• To determine if T-TAS can predict clinical outcomes such as periprocedural bleeding and thrombosis.

Main Methods:

• Utilized the Total Thrombus-Formation Analysis System (T-TAS), a microchip-based flow chamber, to evaluate whole blood thrombogenicity under simulated in vivo conditions.
• Analyzed thrombus formation using T-TAS PL and AR chips, focusing on the area under the flow pressure curve (AUC).
• Evaluated T-TAS performance in patients with coronary artery disease undergoing percutaneous coronary intervention, atrial fibrillation patients undergoing catheter ablation, and patients after total knee arthroplasty.

Main Results:

• The T-TAS PL chip AUC accurately reflects primary hemostasis and is sensitive to antiplatelet therapy effects in coronary artery disease patients.
• Low T-TAS PL AUC results significantly predict periprocedural bleeding events in patients undergoing percutaneous coronary intervention.
• The T-TAS AR chip AUC is effective in assessing direct oral anticoagulant and warfarin efficacy in atrial fibrillation patients and predicts bleeding and thrombosis risk.

Conclusions:

• The Total Thrombus-Formation Analysis System (T-TAS) provides a quantitative measure of whole blood thrombogenicity.
• T-TAS is a valuable tool for monitoring the efficacy of various antithrombotic agents, including dual antiplatelet therapy and direct oral anticoagulants.
• T-TAS serves as a useful index for evaluating the overall antithrombotic effect of combination therapies in diverse cardiovascular conditions and predicting clinical outcomes.